XKRX
004310
Market cap135mUSD
Oct 08, Last price
7,760.00KRW
1D
-5.02%
1Q
58.85%
Jan 2017
63.58%
Name
Hyundai Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Seoul, South Korea, Hyundai Pharmaceutical Co., Ltd. is an international manufacturer and distributor of a diverse portfolio that includes pharmaceutical products, health food beverages, and medical equipment. The company's extensive offerings comprise both prescription (ETC) and over-the-counter (OTC) remedies, addressing a broad spectrum of therapeutic areas. These encompass conditions related to cardiovascular health, infectious diseases, the central nervous system, pain management, respiratory ailments, dermatological issues, digestive and endocrine system disorders, gynecological health, and ophthalmic care. Additionally, their range extends to nutritional supplements, diagnostic reagents, wound healing solutions, and treatments for allergies, arthritis, and anemia, among many others. The company was founded in 1965.
Key people
Han Gu Lee
Chairman · since 2023
Sang Jun Lee
President, Chief Executive Officer, Director · since 2018
Yi Sun Hwang
Vice President · since 2006
Seong Heon Kim
Vice President · since 2020
Chi Yong Kim
Managing Director · since 2021
Ju Hwan Lee
Managing Director · since 2022
Jae Hun Lee
Managing Director · since 2021
Yu Hyeon Park
Managing Director · since 2024
Sin Suk Ryu
Managing Director
Taek Sang Woo
Managing Director · since 2022
Yeong Dong Cha
Assistant Managing Director · since 2023
Jae Pil Gwon
Assistant Managing Director · since 2023
Jun Cheol Ha
Assistant Managing Director · since 2024
Yeong Wuk Jang
Assistant Managing Director · since 2022
Jae Hwon Lee
Assistant Managing Director · since 2024
Seok Ho Lee
Assistant Managing Director · since 2024
Chang Ho Shin
Assistant Managing Director
Yong Hun Choi
Non-Executive Independent Director · since 2024
Byeong Jun Jeon
Non-Executive Independent Director · since 2024
Yeong Gi Kim
Non-Executive Independent Director · since 2023
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑11 | 2024‑11 | 2023‑11 | 2022‑11 | 2021‑11 | 2020‑11 | 2019‑11 | 2018‑11 | 2017‑11 | 2016‑11 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||